Rituximab for the treatment of systemic sclerosis-interstitial lung disease

Rheumatology (Oxford). 2021 Feb 1;60(2):489-491. doi: 10.1093/rheumatology/keaa675.

Authors

Michael Hughes¹, Christopher P Denton², Dinesh Khanna³

Affiliations

¹ Department of Rheumatology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals Foundation Trust, Sheffield, UK.
² Department of Rheumatology, Royal Free Hospital, University College London, London, UK.
³ Scleroderma Program, University of Michigan, Ann Arbor, MI, USA.

PMID: 33244601
DOI: 10.1093/rheumatology/keaa675

No abstract available

Publication types

Comment

MeSH terms

Humans
Lung Diseases, Interstitial* / drug therapy
Rituximab / therapeutic use
Scleroderma, Systemic* / drug therapy

Substances

Rituximab